Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market

01 Aug 2018

CEO Ian Read offers view of what’s ahead in US drug pricing reform based on his recent meeting with President Trump at the White House.

HHS action to restrict negotiated drug rebates in government-sponsored insurance would likely be rapidly adopted in the commercial insurance market as well, Pfizer Inc. CEO Ian Read predicted during the company’s second quarter earnings call July 31.

Read expressed support for HHS action to restrict rebates by revising the existing safe harbor from the Anti-Kickback Statute for...